TY - JOUR T1 - Correlation of SARS-CoV-2 Breakthrough Infections to Time-from-vaccine; Preliminary Study JF - medRxiv DO - 10.1101/2021.07.29.21261317 SP - 2021.07.29.21261317 AU - Barak Mizrahi AU - Roni Lotan AU - Nir Kalkstein AU - Asaf Peretz AU - Galit Perez AU - Amir Ben-Tov AU - Gabriel Chodick AU - Sivan Gazit AU - Tal Patalon Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/31/2021.07.29.21261317.abstract N2 - The short-term effectiveness of a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was widely demonstrated. However, long term effectiveness is still unknown. A nationwide vaccination campaign was initiated early in Israel, allowing for a real-world evaluation of the interaction between protection and time-from-vaccine. The Delta (B.1.617.2) variant became the dominant strain in Israel in June 2021, as Israel is currently experiencing a new surge of cases. Leveraging the centralized computerized database of Maccabi Healthcare Services (MHS), we assessed the correlation between time-from-vaccine and incidence of breakthrough infection. We found that the risk for infection was significantly higher for early vaccinees compared to those vaccinated later. This preliminary finding should prompt further investigagions into long-term protection against different strains, and prospective clinical trials to examine the effect of a booster vaccine against breakthrough infection.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is a retrospective studyFunding StatementFunded by Maccabi health careAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:local ethics committee Maccabi health care servicesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData not available due to ethical restrictions ER -